Clinical trial
Guanfacine to Treat Borderline Personality Disorder
NCT00358969 · Icahn School of Medicine at Mount Sinai, Other · Unknown status
Key facts
| NCT number | NCT00358969 |
|---|---|
| Title | Guanfacine to Treat Borderline Personality Disorder |
| Official title | Guanfacine in the Treatment of Borderline Personality Disorder |
| Lead sponsor | Icahn School of Medicine at Mount Sinai, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | guanfacine (Tenex) |
| Start date | Jul 1, 2006 |
| First posted | Aug 1, 2006 |
| Last update posted | Aug 1, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: